rosiglitazone has been researched along with lt175 in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Crestani, M; Fracchiolla, G; Fruchart, JC; Godio, C; Laghezza, A; Lavecchia, A; Loiodice, F; Mitro, N; Novellino, E; Pinelli, A; Staels, B; Tortorella, V | 1 |
| Aschi, M; Crestani, M; Fracchiolla, G; Gilardi, F; Godio, C; Laghezza, A; Lavecchia, A; Loiodice, F; Mazza, F; Montanari, R; Novellino, E; Pochetti, G; Saccoccia, F; Scotti, E; Tortorella, P | 1 |
| Conte Camerino, D; Fracchiolla, G; Laghezza, A; Lavecchia, A; Loiodice, F; Mazza, F; Montanari, R; Novellino, E; Piemontese, L; Pierno, S; Pochetti, G; Tortorella, P | 1 |
| Capelli, D; Di Giovanni, C; Faliti, S; Fracchiolla, G; Iacobazzi, V; Infantino, V; Laghezza, A; Lavecchia, A; Loiodice, F; Montanari, R; Piemontese, L; Pochetti, G; Tortorella, P | 1 |
| Carbonara, G; Carrieri, A; Crestani, M; De Rosas, M; Fracchiolla, G; Gilardi, F; Giudici, M; Laghezza, A; Lavecchia, A; Loiodice, F; Parente, M; Piemontese, L; Tortorella, P | 1 |
| Carbonara, G; Carrieri, A; Crestani, M; Desvergne, B; Fracchiolla, G; Gilardi, F; Laghezza, A; Lavecchia, A; Loiodice, F; Parente, M; Piemontese, L; Sblano, S; Tauro, M; Tortorella, P | 1 |
| Capelli, D; Cerchia, C; Crestani, M; Giudici, M; Laghezza, A; Lavecchia, A; Loiodice, F; Montanari, R; Peiretti, F; Piemontese, L; Pochetti, G; Tortorella, P | 1 |
| Altieri, F; Awaishima, H; Barendregt, A; Brunel, JM; Capelli, D; Grottesi, A; Heck, AJR; Itoh, T; Loiodice, F; Montanari, R; Nishikata, K; Paiardini, A; Pedone, E; Peiretti, F; Pirone, L; Pochetti, G; Yamamoto, K | 1 |
8 other study(ies) available for rosiglitazone and lt175
| Article | Year |
|---|---|
Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
Topics: 3T3 Cells; Adipocytes; Animals; Binding Sites; Cell Differentiation; Cell Line, Tumor; Clofibric Acid; Endopeptidase K; Fibroblasts; Humans; Ligands; Mice; Models, Molecular; Phenylpropionates; PPAR alpha; PPAR gamma; Protein Conformation; Quantitative Structure-Activity Relationship; Stereoisomerism; Trypsin | 2005 |
Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
Topics: Animals; Biphenyl Compounds; Chemistry, Pharmaceutical; Crystallography, X-Ray; Drug Design; Humans; Hypoglycemic Agents; Ligands; Mice; Models, Chemical; Models, Molecular; Molecular Conformation; Phenylpropionates; PPAR alpha; PPAR gamma; Protein Conformation; Protein Structure, Tertiary | 2008 |
New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function.
Topics: Animals; Cell Line, Tumor; Chloride Channels; Chlorides; Clofibric Acid; Crystallography, X-Ray; Drug Discovery; Electric Conductivity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ligands; Male; Models, Molecular; Molecular Conformation; Muscle, Skeletal; Muscular Diseases; PPAR alpha; PPAR gamma; Propionates; Rats; Rats, Wistar; Rest; Stereoisomerism; Substrate Specificity | 2009 |
New 2-(aryloxy)-3-phenylpropanoic acids as peroxisome proliferator-activated receptor α/γ dual agonists able to upregulate mitochondrial carnitine shuttle system gene expression.
Topics: Calorimetry; Carnitine O-Palmitoyltransferase; Cell Line, Tumor; Crystallography, X-Ray; Humans; Membrane Transport Proteins; Mitochondrial Proteins; Molecular Docking Simulation; PPAR alpha; PPAR gamma; Propionates; Protein Conformation; Stereoisomerism; Structure-Activity Relationship; Thermodynamics; Transcriptional Activation; Up-Regulation | 2013 |
Molecular determinants for nuclear receptors selectivity: chemometric analysis, dockings and site-directed mutagenesis of dual peroxisome proliferator-activated receptors α/γ agonists.
Topics: Algorithms; Amino Acid Sequence; Binding Sites; Binding, Competitive; Clofibric Acid; Computer Simulation; Crystallography, X-Ray; Hep G2 Cells; Humans; Hypolipidemic Agents; Ligands; Models, Molecular; Molecular Sequence Data; Molecular Structure; Mutagenesis, Site-Directed; Phenylacetates; PPAR alpha; PPAR gamma; Protein Structure, Tertiary; Quantitative Structure-Activity Relationship; Thermodynamics | 2013 |
Design, synthesis and biological evaluation of a class of bioisosteric oximes of the novel dual peroxisome proliferator-activated receptor α/γ ligand LT175.
Topics: Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; Humans; Ligands; Molecular Docking Simulation; Molecular Structure; Oximes; PPAR alpha; PPAR gamma; Structure-Activity Relationship | 2015 |
Identification of the First PPARα/γ Dual Agonist Able To Bind to Canonical and Alternative Sites of PPARγ and To Inhibit Its Cdk5-Mediated Phosphorylation.
Topics: 3T3-L1 Cells; Animals; Crystallography, X-Ray; Cyclin-Dependent Kinase 5; Drug Discovery; Enzyme Inhibitors; Hep G2 Cells; Humans; Mice; Models, Molecular; Molecular Structure; Phosphorylation; PPAR alpha; PPAR gamma; Propionates; Protein Conformation; Structure-Activity Relationship | 2018 |
Insights into PPARγ Phosphorylation and Its Inhibition Mechanism.
Topics: Amino Acid Sequence; Biphenyl Compounds; Cyclin-Dependent Kinase 5; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutagenesis, Site-Directed; Mutation; Nerve Tissue Proteins; Phenylpropionates; Phosphorylation; PPAR gamma; Protein Binding; Protein Conformation; Serine | 2020 |